Skip to main content

Table 2 Adherence to statins at 12 months follow-up between participants randomised to usual care (control) or the 3R intervention

From: Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial

Variables

Number of participants (%)

Adjusted at follow-upa

Adjusted at follow-up*

Total**

Control

Total**

Intervention

Odds ratio (95% CI)

P value

Odds ratio (95% CI)

P value

Complete caseb

 Statin adherence (urine)

66

36 (55)

54

34 (63)

0.91 (0.31 to 2.67)

0.860

1.37 (0.66 to 2.88)

0.399

 Statin adherence (MMAS)

95

36 (38)

79

37 (47)

1.82 (0.89 to 3.74)

0.103

1.46 (0.79 to 2.69)

0.227

Intention to treatc

 Statin adherence (urine)

107

62 (57)

105

66 (63)

0.79 (0.30 to 2.09)

0.638

1.24 (0.62 to 2.47)

0.541

 Statin adherence (MMAS)

107

39(36)

105

48 (46)

1.81 (0.89 to 3.67)

0.101

1.48 (0.82 to 2.69)

0.193

Per protocold

 Statin adherence (urine)

66

36 (55)

48

31 (61)

0.88 (0.30 to 2.61)

0.824

1.25 (0.59 to 2.64)

0.560

 Statin adherence (MMAS)

95

36 (38)

74

36 (49)

1.93 (0.93 to 3.99)

0.076

1.55 (0.83 to (2.90)

0.164

Urine-MMAS datae

95

47 (50)

80

46 (58)

0.97 (0.48 to 1.99)

0.945

1.37 (0.75 to 2.50)

0.301

  1. CI confidence interval
  2. *Adjusted for stratification factors: sex and age; odds ratio > 1 favours intervention
  3. **Total number includes all participants who had either a urine test or if urine test is not performed, MMAS data available at 12 months
  4. aAdjusted for stratification factors: sex and age and baseline value; odds ratio > 1 favours intervention
  5. bParticipants with missing outcome data or missing variables required for the model adjustment were excluded
  6. cMissing data imputed using multiple imputation
  7. dParticipants who did not engage with at least one group session of the programme have been excluded from the intervention arm
  8. eMorisky Medication Adherence Scale (MMAS) was used by adding the MMAS adherence data where urine adherence data were missing, using a high score of 8 to indicate high adherence. Use of the©MMAS is protected by US and international copyright laws. Permission for use is required. A licence agreement is available from Donald E. Morisky, MMAS Research (MORISKY), 294 Lindura Court, Las Vegas, NV 89138-4632; dmorisky@gmail.com